Safety and immunogenicity of IMVAMUNE smallpox vaccine using different strategies for a post event scenario.

Authors :: Frey, Sharon E.
Winokur, Patricia L.
Salata, Robert A.
El-Kamary, Samer S.
Turley, Christine B.
Walter, Emmanuel B.
Hay, Christine Mhorag
Newman, Frances K.
Hill, Heather R.
Zhang, Ying
Chaplin, Paul
Tary-Lehmann, Magdalena
Belshe, Robert B.
Source :: Vaccine. Jun2013, Vol. 31 Issue 29, p3025-3033. 9p.
Publication Year :: 2013
Abstract: Highlights: [•] Reintroduction of Variola major as an agent of bioterrorism remains a concern. [•] A compressed schedule of MVA was evaluated for use in a post event scenario. [•] MVA is well tolerated when given as two standard doses at Days 0 and 28 or 0 and 7. [•] A 2nd dose of MVA at Day 28 compared to Day 7 provided greater antibody responses. [•] INF-γ expression was greatest within 2 weeks after last vaccination. [ABSTRACT FROM AUTHOR]

Subjects :: *SMALLPOX vaccines
*VACCINE safety
*IMMUNOGENETICS
*BIOTERRORISM
*INF (Computer program language)
*IMMUNOGLOBULINS
*IMMUNE response
*DRUG dosage

Full Text Access

Tools